DYAX: Dyax Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DYAX: Dyax Corp.

DYAX 38.41

0.0%

Jan 25 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (42)	9/25/2002 11:11:58 AM
From: keokalani'nui	Read Replies (1) of 197

Dyax: DX-88 Clinical Trial Interim Results Positive Wednesday September 25, 9:39 am ET CAMBRIDGE, Mass. -(Dow Jones)- Dyax Corp. (NasdaqNM:DYAX - News) said all five patients in a study of its DX-88 compound for the treatment of acute hereditary angioedema showed symptomatic relief within three hours of taking the treatment. The primary endpoint of the trial was symptomatic relief within four hours of treatment for the condition, which is characterized by acute episodic attacks of swelling in body parts. Four of five patients treated with the company's DX-88 compound for acute hereditary angioedema responded favorably and tolerated the compound well. One patient had an allergic reaction but responded quickly and completely with standard medical therapy, Dyax said in a press release. The five patients studied suffer from various manifestations of HAE attacks. Two patients were given 10 milligram and 40 milligram doses, while the remaining three received 10 milligram doses. Dyax expects to complete the European study by early 2003 and has started enrolling patients for a second DX-88 study.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next